No Patient Left Behind Revenue and Competitors
Estimated Revenue & Valuation
- No Patient Left Behind's estimated annual revenue is currently $8.3M per year.
- No Patient Left Behind's estimated revenue per employee is $140,000
Employee Data
- No Patient Left Behind has 59 Employees.
- No Patient Left Behind grew their employee count by 638% last year.
No Patient Left Behind's People
Name | Title | Email/Phone |
---|---|---|
1 | Deputy Director | Reveal Email/Phone |
2 | Biotech Fellow | Reveal Email/Phone |
No Patient Left Behind Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $15M | 366 | 3% | N/A | N/A |
#2 | $5.2M | 37 | 9% | N/A | N/A |
#3 | $7.6M | 54 | -2% | N/A | N/A |
#4 | $15M | 99 | 5% | N/A | N/A |
#5 | $1.7M | 27 | 17% | N/A | N/A |
#6 | $7.5M | 87 | 13% | N/A | N/A |
#7 | $35M | 271 | 6% | N/A | N/A |
#8 | $3.5M | 56 | -2% | N/A | N/A |
#9 | $4.9M | 35 | 3% | N/A | N/A |
#10 | $7.5M | 166 | 1% | N/A | N/A |
What Is No Patient Left Behind?
We believe it is possible for Americans to be able to afford the medicines of today and tomorrow. No Patient Left Behind is a non-profit dedicated to promoting reforms of America’s healthcare system and drug industry that would ensure that 1) all patients have proper health insurance with no/low out-of-pocket costs so they can afford the treatments they need and 2) that all drugs go generic when it’s their time so that America gets value for what it invests in branded medicines while 3) preserving the incentives for further biomedical innovation for all the patients still waiting for their cure.
keywords:N/AN/A
Total Funding
59
Number of Employees
$8.3M
Revenue (est)
638%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $7.7M | 59 | -26% | N/A |
#2 | $7.7M | 59 | 34% | N/A |
#3 | $15.2M | 59 | 4% | N/A |
#4 | $3.5M | 59 | -5% | N/A |
#5 | $7.7M | 59 | N/A | N/A |